For instance, upgrading from ICI monotherapy to combination treatment (i.e., dual ICI treatment or ICI plus tyrosine kinase inhibitors/anti-VEGF [vascular endothelial growth factor]) or using a different combination than the previous ICI regimen may restore the efficacy of immunotherapy by synergistically modulating the immunosuppressive tumor immune microenvironment through different mechanisms.[12], [13], [14] This may also be achieved by only switching the combination partner (i.e., TKI/anti-VEGF) while continuing with the same ICI. This evidence concerns the gene VEGFA and neoplasm.